MEDORIL Capsule Ref.[28132] Active ingredients: Calcium dobesilate

Source: Υπουργείο Υγείας (CY)  Revision Year: 2014  Publisher: MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus

5.1. Pharmacodynamic properties

Pharmacotherapeutic group: Other sclerosing agents, vasoprotectives
ATC code: C05BX01

Calcium dobesilate is an angioprotective agent acting in 3 sites:

  • The capillary wall in which it increases the resistance and reduces the permeability.
  • The lymph flow which it activates.
  • The blood flow which it promotes by reducing whole blood and plasma viscosity, correcting the albumin/globulin ratio, lowering platelet hyperaggreability and increasing erythrocyte flexibility.

Calcium dobesilate has been shown to inhibit vasoactive substances, to reduce endothelemia and to improve the biosynthesis of basement membrane collagen.

5.2. Pharmacokinetic properties

After oral administration the maximum serum concentration is achieved in about 6 hours. 20 to 25% is bound to plasma proteins. Approximately 10% of the drug is metabolized. 75% is excreted unchanged in the urine and the remaining 25% in faeces. The half life of the drug in plasma is 5 hours, while the elimination half life varies form 2.5 to 15 hours.

5.3. Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.

< Previous: Precautions

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈